Artiva Biotherapeutics (ARTV) vs Cabaletta Bio (CABA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Artiva Biotherapeutics (ARTV) has outperformed Cabaletta Bio (CABA) over the past year, gaining 20.8% versus a loss of 55.0%. Cabaletta Bio is the larger company by market cap ($201.9 million vs $186.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARTV | CABA |
|---|---|---|
| Share price | $3.78 | $0.9361 |
| Market cap | $186.85M | $201.94M |
| 1-day change | -1.31% | -7.32% |
| YTD return | -11.89% | -57.26% |
| 1-year return | +20.77% | -55.00% |
| 5-year return | — | -91.93% |
| EPS (TTM) | $-2.85 | $-1.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-83.86M | $-167.86M |
| 52-week high | $14.53 | $4.23 |
| 52-week low | $2.96 | $0.93 |
| Distance from 52-week high | -73.98% | -77.87% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +448.94% | +1155.21% |
| Average volume | 792.26K | 5.15M |
| Shares outstanding | 49.43M | 215.72M |
| Employees | 134 | 154 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARTV has outperformed CABA by 75.8 percentage points over the past year.
About Artiva Biotherapeutics
ARTV stock →Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees
About Cabaletta Bio
CABA stock →Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 154 employees
ARTV vs CABA FAQ
Which is bigger, Artiva Biotherapeutics or Cabaletta Bio?
Cabaletta Bio (CABA) is larger, with a market capitalization of $201.94M compared with $186.85M for Artiva Biotherapeutics (ARTV).
Which stock has performed better over the past year, ARTV or CABA?
ARTV returned +20.77% over the past 12 months, compared with -55.00% for CABA (price return, excluding dividends). Past performance does not predict future results.
Are Artiva Biotherapeutics and Cabaletta Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.